{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:10:05Z","timestamp":1758568205405,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"am","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.therap.2020.06.014","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T11:31:31Z","timestamp":1593775891000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolution of clotting factor concentrates prescriptions and impact of recommendations of prophylaxis in children with haemophilia"],"prefix":"10.1016","volume":"76","author":[{"given":"Florianne","family":"Bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lienhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alban","family":"Revy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4443-1609","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Chamouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.06.014_bib0100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.06.014_bib0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2516.2002.00581.x","article-title":"Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients","volume":"8","author":"Royal","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.therap.2020.06.014_bib0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1016\/j.therap.2020.06.014_bib0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V106.11.3.3","article-title":"Initial results of a randomised, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency","volume":"106","author":"Manco-Johnson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.therap.2020.06.014_bib0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia prophylaxis in Sweden","volume":"65","author":"Nilsson","year":"1976","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.therap.2020.06.014_bib0125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients\u00a0\u2013\u00a0A long-term follow-up","volume":"241","author":"L\u00f6fqvist","year":"1997","journal-title":"J Intern Med"},{"key":"10.1016\/j.therap.2020.06.014_bib0130","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe haemophilia A: interim results from the first 5\u00a0years of the Canadian Haemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.therap.2020.06.014_bib0135","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jpeds.2012.11.080","article-title":"Use of clinical practice guidelines on long-term prophylaxis in severe haemophilia in France: a retrospective audit","volume":"162","author":"Meunier","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.therap.2020.06.014_bib0140","first-page":"1571","article-title":"French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy","volume":"16","author":"Meunier","year":"2009","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.therap.2020.06.014_bib0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","article-title":"The cost of severe haemophilia in Europe: the CHESS study","volume":"12","author":"O\u2019Hara","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.therap.2020.06.014_bib0150","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mpd.2002.128115","article-title":"What factors influence the age at diagnosis of haemophilia? Results of the French haemophilia cohort","volume":"141","author":"Chambost","year":"2002","journal-title":"J Pediatr"},{"key":"10.1016\/j.therap.2020.06.014_bib0155","series-title":"La prise en charge des patients atteints d\u2019une maladie h\u00e9morragique h\u00e9r\u00e9ditaire","first-page":"6","author":"Cohorte France Coag.","year":"2014"},{"key":"10.1016\/j.therap.2020.06.014_bib0160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1651-2227.1990.tb11438.x","article-title":"Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases","volume":"79","author":"Ljung","year":"1990","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.therap.2020.06.014_bib0165","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1538-7836.2004.00731.x","article-title":"Is the incidence and prevalence of inhibitors greater with recombinant products? Yes","volume":"2","author":"Aledort","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.therap.2020.06.014_bib0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","article-title":"Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A","volume":"107","author":"Goudemand","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.therap.2020.06.014_bib0175","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2014-07-586347","article-title":"Recombinant factor VIII products and inhibitor development in previously untreated boys with severe haemophilia A","volume":"124","author":"Calvez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.therap.2020.06.014_bib0180","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jth.12113","article-title":"Musculoskeletal health of subjects with haemophilia A treated with tailored prophylaxis: Canadian Haemophilia Primary Prophylaxis (CHPS) Study","volume":"11","author":"Hilliard","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.therap.2020.06.014_bib0185","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2141.2001.02580.x","article-title":"Long-term outcome of individualised prophylactic treatment of children with severe haemophilia","volume":"112","author":"Van Den Berg","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.therap.2020.06.014_bib0190","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V99.7.2337","article-title":"The effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia","volume":"99","author":"Fischer","year":"2002","journal-title":"Blood"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720301190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:31Z","timestamp":1758567211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720301190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0040595720301190"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.014","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of clotting factor concentrates prescriptions and impact of recommendations of prophylaxis in children with haemophilia","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}